Trump's 100% tariff on pharma will not impact generic makers, says Indian Pharma Alliance

The Indian Pharmaceutical Alliance clarifies that Trump's proposed 100% tariff targets patented and branded drugs, not generics, potentially impacting a segment of Indian exports. While the immediate effect on Indian exports may be limited due to their focus on generics and existing US manufacturing presence, the industry is advised to prepare for future policy changes and explore advanced pharmaceutical opportunities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ctv2JXp
via IFTTT